SCHEMBL2015803

SCHEMBL2015803

Cc1c(C(=O)OCC2CCCO2)[nH]c2c1C(=O)CC(c1ccco1)C2

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 16/20 1.00
PKM P14618 12/20 1.00
POLB P06746 12/20 1.00
SMN1; SMN2 Q16637 11/20 1.00
LMNA P02545 10/20 1.00
L3MBTL1 Q9Y468 10/20 1.00
MAPT P10636 8/20 1.00
TDP1 Q9NUW8 7/20 1.00
ESR1 P03372 5/20 1.00
RECQL P46063 4/20 1.00
APEX1 P27695 3/20 1.00
KDM4E B2RXH2 3/20 1.00
HPGD P15428 3/20 1.00
BLM P54132 2/20 1.00
THRB P10828 1/20 1.00
NR4A1 P22736 1/20 1.00
CACNA1B Q00975 1/20 1.00
APBA1 Q02410 1/20 1.00
HSD17B10 Q99714 8/20 0.73
TSHR P16473 7/20 0.73

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2017664 0.86 ALDH1A1 (0.77) ALDH1A1PKMPOLBSMN1; SMN2LMNA
SCHEMBL2014912 0.85 POLB (1.00) ALDH1A1PKMPOLBSMN1; SMN2LMNA
SCHEMBL10090671 0.83 SMN1; SMN2 (0.72) ALDH1A1PKMPOLBSMN1; SMN2LMNA
SCHEMBL2016888 0.82 POLB (0.84) ALDH1A1PKMPOLBSMN1; SMN2LMNA
SCHEMBL2016219 0.82 SMN1; SMN2 (0.87) ALDH1A1PKMPOLBSMN1; SMN2LMNA
SCHEMBL2015501 0.82 POLB (1.00) ALDH1A1PKMPOLBSMN1; SMN2LMNA
SCHEMBL2019581 0.82 POLB (1.00) ALDH1A1PKMPOLBSMN1; SMN2LMNA
SCHEMBL2016416 0.81 POLB (0.80) ALDH1A1PKMPOLBSMN1; SMN2LMNA
SCHEMBL2016203 0.81 POLB (1.00) ALDH1A1PKMPOLBSMN1; SMN2LMNA
SCHEMBL2020480 0.81 ALDH1A1 (1.00) ALDH1A1PKMPOLBSMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011073929-A1 6-(2-FURYL)-3-METHYL-4-OXO-1,5,6,7-TETRAHYDROINDOLE-2-CARBOXYLATE DERIVATIVES AND USES THEREOF ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) 2011-06-23 WO claimed
WO-2023077077-A1 RNA DEGRADERS AND USES THEREOF ARRAKIS THERAPEUTICS, INC. (US) 2023-05-04 WO disclosed
WO-2011073929-A1 6-(2-FURYL)-3-METHYL-4-OXO-1,5,6,7-TETRAHYDROINDOLE-2-CARBOXYLATE DERIVATIVES AND USES THEREOF ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) 2011-06-23 WO disclosed
WO-2011073929-A1 6-(2-FURYL)-3-METHYL-4-OXO-1,5,6,7-TETRAHYDROINDOLE-2-CARBOXYLATE DERIVATIVES AND USES THEREOF ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) 2011-06-23 WO disclosed
US-20090118135-A1 METHODS AND COMPOUNDS FOR REGULATING APOPTOSIS THE BURNHAM INSTITUTE (US) 2009-05-07 US disclosed
US-20090118135-A1 METHODS AND COMPOUNDS FOR REGULATING APOPTOSIS THE BURNHAM INSTITUTE (US) 2009-05-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118135-A1 METHODS AND COMPOUNDS FOR REGULATING APOPTOSIS BCL2, BAX, BAD ALDH1A1 3724/4885PKM 4036/4885POLB 1539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.